Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zander

Showing results (61-70 of 206) with videos related to

Pageof 21
Sort By:
Journal of Biomechanics|September 27, 2017
Spinal loads and trunk muscles forces during level walking - A combined in vivo and in silico study on six subjectsRizwan Arshad, Lorenza Angelini, Thomas Zander, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathwayMartin L Sos, Thomas Zander, Roman K Thomas, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|January 11, 2015
[Surgical therapy for pulmonary metastases from malignant melanoma]Sascha Macherey, Max Schlaak, Fabian Doerr, et al.
Journal of Biomechanics|February 3, 2015
In vivo implant forces acting on a vertebral body replacement during upper body flexionMarcel Dreischarf, Laia Albiol, Thomas Zander, et al.
Diagnostic Pathology|March 28, 2024
Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case reportTillmann Bedau, Carina Heydt, Udo Siebolts, et al.
Oncology Letters|August 7, 2023
Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic targetDuygu Akca, Adrian Simon, Reinhard Buettner, et al.
Pharmacogenomics|August 18, 2010
CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancerRalf Metzger, Lukas Heukamp, Uta Drebber, et al.
International Journal of Cancer|July 3, 2026
MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate TherapyTillmann Bedau, Thomas Zander, Hans Anton Schlößer, et al.
Oncology Reports|December 22, 2007
Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMFUdo Siebolts, Jürgen Thiele, Thomas Zander, et al.
Journal of Cancer Research and Clinical Oncology|April 28, 2022
Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinomaAlexander Damanakis, Patrick Sven Plum, Florian Gebauer, et al.
Pageof 21

Showing results (61-70 of 206) with videos related to

Sort By:
Pageof 21
Journal of Biomechanics|September 27, 2017
Spinal loads and trunk muscles forces during level walking - A combined in vivo and in silico study on six subjectsRizwan Arshad, Lorenza Angelini, Thomas Zander, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 28, 2008
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathwayMartin L Sos, Thomas Zander, Roman K Thomas, et al.
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|January 11, 2015
[Surgical therapy for pulmonary metastases from malignant melanoma]Sascha Macherey, Max Schlaak, Fabian Doerr, et al.
Journal of Biomechanics|February 3, 2015
In vivo implant forces acting on a vertebral body replacement during upper body flexionMarcel Dreischarf, Laia Albiol, Thomas Zander, et al.
Diagnostic Pathology|March 28, 2024
Concurrent KRAS p.G12C mutation and ANK3::RET fusion in a patient with metastatic colorectal cancer: a case reportTillmann Bedau, Carina Heydt, Udo Siebolts, et al.
Oncology Letters|August 7, 2023
Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic targetDuygu Akca, Adrian Simon, Reinhard Buettner, et al.
Pharmacogenomics|August 18, 2010
CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancerRalf Metzger, Lukas Heukamp, Uta Drebber, et al.
International Journal of Cancer|July 3, 2026
MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate TherapyTillmann Bedau, Thomas Zander, Hans Anton Schlößer, et al.
Oncology Reports|December 22, 2007
Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMFUdo Siebolts, Jürgen Thiele, Thomas Zander, et al.
Journal of Cancer Research and Clinical Oncology|April 28, 2022
Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinomaAlexander Damanakis, Patrick Sven Plum, Florian Gebauer, et al.
Pageof 21